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We evaluated  phenotypic  markers  in  full-genome  sequences  of  avian  inﬂuenza  isolates
to  identify  avian  strains  with  increased  potential  for  transmission  and  pathogenicity  in
mammals.  Of  149 markers  examined,  67 were  positive  in  the  consensus  sequences  from
206 avian  isolates.  Analysis  of  deep  sequencing  data  in a subset  of 24  isolates  revealed
that  344  subpopulations  occurred  at marker  positions.  Markers  in  subpopulations  wereeywords:
vian inﬂuenza virus
urveillance
ost adaptation
henotype markers
nﬂuenza research
atabase
signiﬁcantly  more  likely  to be negative  (258/344)  than  positive  (86/344),  but  nearly  all  of the
marker-positive  subpopulations  (78/86)  were  associated  with  marker-negative  consensus
sequences.  Our  analysis  revealed  signiﬁcant  variation  in  important  markers  among  avian
isolates, and  showed  that  consensus  sequences  do not  fully  convey  an isolate’s  potential
for  increased  transmissibility  and  pathogenicity  in  mammals.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license. . Introduction
The recent emergence of highly pathogenic avian
nﬂuenza (HPAI) H5N1 and pandemic H1N1 (H1N1pdm)
raphically shows that genotypic and phenotypic changes
n animal inﬂuenza viruses will continue to produce new
uman pathogens [1,2]. If we are to recognize and prepare
or new emerging viruses, we must identify genotypic and
henotypic markers that indicate which animal viruses are
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Open access under CC BYmost transmissible and pathogenic to humans. This is a
formidable challenge given the tremendous genetic diver-
sity of viruses circulating among birds and mammals in
nature [3,4], and since laboratory phenotyping for even a
single amino acid change can involve the use of wild-type
and reverse genetic variants [5–7], culture in multiple cell
lines [8], and experimental infections in rodents [8–10],
guinea pigs [11,12], and ferrets [10,13,14].
Enhanced surveillance [15], coupled with advances in
sequencing and bioinformatics [16], gives us the ability
to develop hypotheses about which strains and subtypes
pose the greatest risk and deserve further scrutiny as
potential human pathogens. An important step in this pro-
cess is to determine whether or not phenotypic markers
deduced from sequence data are useful for assessing risk
[11,17–19]. Phenotypic markers are amino acid substitu-
tions that are suggested to alter pathogenicity and host
tropism of inﬂuenza viruses to increase their likelihood to
be transmitted from an avian to a mammalian host and
cause disease.
-NC-SA license. 
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Table 1
Phenotypic markers (n = 149) reported from inﬂuenza A viruses that were analyzed in this study of 206 full genome sequences. The H5 numbering system
was  used to identify nucleotide positions in our analysis. Markers were identiﬁed by review of existing literature. Asterisks refer to positive markers in the
consensus sequence (*) or subpopulation (**).
Protein AA substitution
(H5
numbering)
Phenotype Identiﬁed in
consensus (*)
or subpop (**)
References
PB2 M28I Increased polymerase activity, Increased virulence in
mammals and birds
** [37,38]
A44S Human host marker [18]
T63I (with PB1
M677T)
Pathogenic in mice * [39]
M64T/I Human host marker *, ** [18]
L89V Enhanced polymerase activity, Increased virulence in
mice
* [40]
A199S Human host marker ** [18,38,41]
D256G Enhanced polymerase activity, Mammalian host
marker
** [42]
T271A Human host marker (host-speciﬁc polymerase activity) *, ** [18,38,43]
A274T Increased polymerase activity, Increased virulence in
mammals and birds
[37]
G309D Enhanced polymerase activity, Increased virulence in
mice
*, ** [40]
R318K Increased virulence in mammals *, ** [5,44]
T339K Enhanced polymerase activity, Increased virulence in
mice
* [40]
R/Q355K Increased virulence in mammals *, ** [5,9,45]
Q368R Increased polymerase activity, Increased virulence in
mammals
*, ** [10,46]
E391Q Increased polymerase activity, Increased virulence in
mammals
** [10,46]
H447Q Increased polymerase activity, Increased virulence in
mammals
*, ** [10,46]
L475M Human host marker (host-speciﬁc polymerase activity) * [18,41,43]
R477G Enhanced polymerase activity, Increased virulence in
mice
* [40]
I495V Enhanced polymerase activity, Increased virulence in
mice
* [40]
K526R Increased polymerase activity, Increased virulence in
mammals and birds (host-speciﬁc polymerase activity)
[37,43]
I553V Increased polymerase activity, Increased virulence in
mammals and birds
* [37]
D567N Human host marker * [18,41]
A588I Human host marker (host-speciﬁc polymerase activity) [18,38,43]
GQ590/591SR Increased polymerase activity, Human host adaptation * [47]
Q591K Increased virulence in mammals [8]
L607V Increased polymerase activity, Increased virulence in
mammals and birds
** [37]
E/D627K/N Human host marker, Enhanced polymerase activity,
Increased virulence in mammals
** [5,8,9,12,13,18,41,42,48–72]
A661T Enhanced Transmission *, ** [38]
V667I Enhanced Transmission * http://www.ﬂudb.org
A/S674T Human host marker [18,38]
A676T Enhanced polymerase active, Increased virulence in
mice
*, ** [40]
D701N Increased polymerase activity, Increased virulence in
mammals, Mammalian host marker
[8,11,12,43,47,58,71,73–77]
K702R Human host marker [18,38,41]
S714R Increased polymerase activity, Increased virulence in
mammals, Mammalian host marker
** [74,77]
PB1 A3V Increased polymerase activity, Increased virulence in
mammals
* [10,46]
L13P Increased polymerase activity, Increased virulence in
mammals, Mammalian host marker
* [74,77]
M51T Increased virulence in ducks [78]
A56V Increased virulence in ducks [78]
G87E Increased virulence in ducks [78]
H99Y Airborne transmissible in mammals [13]
R207K Increased polymerase activity in mammalian cells *, ** [79]
M/V317I Increased virulence in mammals * [9,44,45,80]
K328N Increased polymerase activity, Increased virulence in
mammals
* [10,46]
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Table 1 (Continued)
Protein AA substitution
(H5
numbering)
Phenotype Identiﬁed in
consensus (*)
or subpop (**)
References
I368V Airborne transmissible in mammals [13]
S375N/T Increased polymerase activity, Increased virulence in
mammals, Human host marker
* [10,41,46]
H436Y Increased polymerase activity and virulence in
mallards, ferrets and mice
* [79]
L473V Increased polymerase activity and replication
efﬁciency
* [81]
L598P Increased polymerase activity and replication
efﬁciency
[81]
M677T (with
PB2 T63I)
Pathogenic in mice * [39]
S678N Increased polymerase activity, Increased virulence in
mammals, Mammalian host marker
[74,77]
PB1-F2 N66S Increased virulence in mammals * [82–84]
PA P26L Human host marker [18]
D55N Human host marker *, ** [18,38,41]
R57Q Human host marker * [18]
V100A Human host marker ** [18,38,41]
V127I Increased virulence in mammals [44,85]
S149P Increased polymerase activity, Increased virulence in
mammals and birds
** [37]
S225C Human host marker [18]
H266R Increased polymerase activity, Increased virulence in
mammals and birds
* [37]
L268I Human host marker [18]
L336M Increased virulence in mammals *, ** [44,85]
A337S Human host marker ** [18]
I357K Increased polymerase activity, Increased virulence in
mammals and birds
** [37]
E382D Human host marker *, ** [38,41]
A404S Human host marker *, ** [18]
S409N Enhanced Transmission, Human host marker *, ** [18,38]
S/A515T Increased polymerase activity, Increased virulence in
mammals and birds
* [37,79]
T552S Human host marker [18,38,41]
K615N Increased polymerase activity, Increased virulence in
mammals, Mammalian host marker
[74,77]
HA E75K (with:
S123P, N193K,
R497K)
Increased virus binding to 2,6 ** [19]
A/I/P/S/T86V Increased virulence in mammals * [44,86]
D94N Increased virus binding to 2,6, Enhanced virus fusion *, ** [87]
H103Y (with:
T156A, Q222L,
G224S)
Airborne transmissible in mammals [13]
S121N Increased virus binding to 2,6, Increased replication
in  mammals
[88]
S123P (with:
E75K, N193K,
R497K)
Increased virus binding to 2,6 * [19,89]
N/D124S Increased virulence in mammals * [44,86]
L129V/del
(with: A134V,
I151T)
Increased virus binding to 2,6 * [90,91]
S133A Increased pseudovirus binding to 2,6 * [92]
A134V Increased virus binding to 2,6 [90,93–95]
Q/H/I138L/N Increased virulence in mammals * [44,86]
G139R Increased virus binding to 2,6 [19,96]
I151T (with:
L129V/del)
Increased virus binding to 2,6 * [90,91]
N154D (with:
N220K, Q222L,
N244D, T315I)
Airborne transmissibility in mammals * [14,97]
S155N Increased virus binding to 2,6, Increased replication
in  mammals
*, ** [88,98]
T156A Increased virus binding to 2,6, Airborne transmissible
in mammals
*, ** [11,13,88,98]
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Table 1 (Continued)
Protein AA substitution
(H5
numbering)
Phenotype Identiﬁed in
consensus (*)
or subpop (**)
References
N182K/D Increased virus binding to 2,6 [19,94,96]
E183G Increased virus binding to 2,6 [99,100]
E186G/D Increased virus binding to 2,6 * [99,100]
T188I Increased pseudovirus binding to 2,6 * [92]
K189S/R Increased virus binding to 2,6, Increased replication
in mammals
*, ** [88,100]
Q192R/H Increased virus binding to 2,6 ** [19,91,96,99]
N193K Increased virus binding to 2,6 *, ** [19]
S205Y Increased virus binding to 2,6 * [101]
V210I Increased virus binding to 2,6 *, ** [91]
K212E/R/G Increased virulence in mammals * [44,86]
K218E Altered pathogenicity and tissue tropism in mice [94,102]
N220K (with:
N154D, Q222L,
T315I)
Airborne transmissible in mammals ** [14,103]
D221G Change in receptor binding afﬁnity from human to
avian receptors
[103–106]
Q222L Increased virus binding to 2,6, Airborne transmissible
in mammals
[13,14,97,107,108]
S223N Increased virus binding to 2,6 [88,94,96,98–100,109,110]
G224S Increased virus binding to 2,6, Airborne transmissible
in mammals
[13,88,96,98–100,105,108]
P235S Increased virus binding to 2,6 *, ** [91]
E251K Increased virus binding to 2,6 [99]
A263T Increased virulence in mammals *, ** [44,86]
T315I (with:
N154D, N220K,
Q222L)
Airborne transmissible in mammals *, ** [14]
K388I Decreased pH of fusion, Increased HA stability,
Increased replication efﬁciency in mice
[111,112]
E435K Decreased pH of fusion [112]
N444K Increased pH of fusion [112]
R497K (with:
E75K, S123P,
N193K)
Increased virus binding to 2,6 * [19]
NP G16D Human host marker ** [18]
I61L Human host marker [18,38]
R99K Airborne transmissible in mammals ** [13]
L136M Enhanced Transmission * [38]
L283P Human host marker ** [18,38]
R305K Human host marker * [18]
F313Y Human host marker ** [18,38]
N319K Increased polymerase activity, Mammalian host
marker
* [74,75]
S345N Airborne transmissible in mammals [13]
Q357L (with
PB2 I27K)
Increased virulence in mammals, Human host marker [18,75]
NA T223I Increased virulence in mammals [5,9,45]
H275Y Increased virulence in mammals ** [113]
M1 V15I/T Increased virulence in mammals *, ** [5,9,45]
N30D Increased virulence in mammals * [6]
V115I Human host marker [18]
T121A Human host marker ** [18]
T137A Human host marker ** [18,38]
T215A Increased virulence in mammals * [6]
M2 E16G Enhanced Transmission ** [38]
L55F Enhanced Transmission *, ** [38]
NS1 M31I Increased virulence in mammals [85]
A/P42S Increased virulence in mammals, Antagonism of IFN
induction
* [7,44]
I81M Human host marker ** [18]
D87E Increased virulence in mammals [114,115]
T/D92E Increased virulence in mammals, Escape of antiviral
host response
*, ** [9,44,115–117]
L98F Increased virulence in mammals [118,119]
I101M Increased virulence in mammals [118,119]
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Table 1 (Continued)
Protein AA substitution
(H5
numbering)
Phenotype Identiﬁed in
consensus (*)
or subpop (**)
References
T/D/V/R/A127N Increased virulence in mammals *, ** [44,120]
V149A Pathogenicity in mice, Antagonism of IFN induction * [121]
D/G189N Increased virulence in mammals [44,85]
S195T/Y Increased virulence in mammals ** [44,85,122]
N200S (with
NEP/NS2 T47A)
Decreased IFN antagonism ** [93]
G205R (with
NEP/NS2 M51I)
Decreased IFN antagonism ** [93]
P215T Human host marker ** [18]
E227R Human host marker [18]
S228P Increased virulence in mammals *, ** [44]
NEP/NS2 M31I Increased virulence in mammals [44,85]
T47A (with NS1
N200S)
Decreased IFN antagonism [93]
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In this study, we approached the question of whether
olecular markers for increased pathogenicity and trans-
issibility/host tropism in mammals are useful to identify
vian inﬂuenza viruses of public health importance. We
dentiﬁed potentially relevant phenotypic markers from
he literature, and analyzed consensus and deep sequence
ata from viruses isolated from wild birds and the envi-
onment in California. The goal of our study was to answer
he following questions: what molecular markers have
een identiﬁed with potential importance for increased
athogenicity and transmissibility in mammals? Are these
olecular markers present in the consensus sequence of
solates in California (2005–2010)? Are positive markers in
he consensus sequence of Californian isolates associated
ith particular hemagglutinin (HA) subtypes? What viral
ubpopulations can be identiﬁed at the amino acid sites
hat contain the known molecular markers?
. Materials and methods
.1. Virus isolation and sequencing
Full inﬂuenza virus genome sequences were obtained
rom 206 viruses isolated from wild birds and environ-
ental samples collected in California from 2005 to 2010.
iruses were isolated at the University of California, Davis,
y inoculation of embryonated chicken eggs [20,21]. Full
enome sequencing was performed at the J. Craig Venter
nstitute (JCVI) and all generated sequences were assigned
enBank accession numbers (Supplementary Table 1). Iso-
ates with mixed infections (more than a single HA or
euraminidase (NA) subtype) were not included in this
nalysis, nor were isolates sharing >99.8% sequence iden-
ity across all 8 segments (i.e. identical viruses).
Supplementary material related to this article can be
ound, in the online version, at http://dx.doi.org/10.1016/
.cimid.2013.06.003.
Next generation sequencing (NGS) (454, Illumina)
erformed at JCVI was designed to provide 200× cov-
rage of the genome [16]. Consensus sequences were[93]
s ** [44,85]
determined by identifying the predominant base among
all reads at a given nucleotide site. Thus, the consensus
sequences deposited in GenBank reﬂect bases occurring
in the majority of the reads for any given nucleotide
site. Although NGS was primarily used to accomplish high
throughput consensus sequencing, the level of coverage
also yielded deep sequencing analysis data. A subset of
virus isolates (n = 24) was  examined for single nucleotide
polymorphisms (SNPs) to identify subpopulation variants
possessing different amino acids at marker positions than
the consensus sequence.
2.2. Selection and analysis of phenotypic markers
We  performed a literature search to compile an inven-
tory of amino acid mutations reported to be associated
with changes in host tropism or increased pathogenicity
in mammals, and identiﬁed 149 markers for use in this
analysis (Table 1). Sources included published research
and review articles, the H5N1 Genetic Change Inven-
tory published by the Centers for Disease Control and
Prevention (CDC), and the Inﬂuenza Research Database
(http://www.ﬂudb.org). A total of 149 phenotypic markers
were identiﬁed including 34 in PB2, 16 in PB1, 1 in PB1-F2,
18 in PA, 40 in HA, 10 in NP, 2 in NA, 6 in M1,  2 in M2, 16
in NS1 and 4 in NEP/NS2.
Consensus sequence data for the 206 isolates was  ana-
lyzed using tools provided on the IRD website (data was
obtained from the NIAID IRD online through the website at
http://www.ﬂudb.org) [22]. Amino acids at the 149 marker
positions were identiﬁed using the “Identify Point Muta-
tions in proteins” tool on the IRD website, downloaded and
processed in Microsoft Excel. The challenge presented by
the different numbering systems for HA subtypes was  over-
come by preparing an alignment of all HA subtypes and
using this tool to determine nucleotide positions relative
to the H5 numbering system (Fig. 1). Each marker site was
classiﬁed as positive or negative depending on whether
or not the observed amino acid at that site matched the
reported marker phenotype. For example, the presence of
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Fig. 1. Alignment (Clustal Omega) of inﬂuenza A virus mature HA sequences (without the H0 signal peptide) from of H1 to H14 subtypes. The isolates are
named as “Subtype Country Year GenBank Accession#”. H3 subtype is marked in red and H5 subtype is marked in blue. Highly, moderately and weakly
conserved residues are highlighted in black, dark grey, and light grey, respectively. Phenotypic markers for increased virulence or transmissibility (Table 1)
are  highlighted in red.
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Fig. 1. (Continued)
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Fig. 1. (Continued)
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soleucine (I) at amino acid position 28 in the PB2 protein
ould be classiﬁed as positive for the marker PB2 M28I
ﬁrst marker in Table 1). If methionine (M)  or any other
mino acid was observed at position 28, the marker was
lassiﬁed as negative. The frequencies of positive and neg-
tive markers were calculated for each HA subtype, and
e tested the null hypothesis that markers were equally
istributed among HA subtypes using Fisher’s exact test
GraphPad Prism, GraphPad Software, La Jolla CA, USA).
.3. Subpopulation analysis
The CLC Bio ﬁnd variations tool was used to examine
eep sequencing data and identify viral subpopulations.
NPs were deﬁned as subpopulations when >5% of total
eads at any given site differed from the consensus
equence. Output for SNPs included nucleotide position
nd the number of A (Adenine), T (Thymine), G (Guanine),
 (Cytosine) calls or reads, at that site. The corresponding
mino acid position for each SNP was determined by visual
nspection to see if subpopulations occurred at marker
ites. Each subpopulation at a marker site was classiﬁed
s positive or negative as described above for consensus
equences. We  compared subpopulation phenotypes with
onsensus sequence phenotypes and categorized results
nto one of 4 outcomes: (1) phenotypic marker was positive
n the consensus sequence, but negative in the subpopu-
ation; (2) marker was positive in the subpopulation, but
egative in the consensus sequence; (3) marker was  neg-
tive in the subpopulation and the consensus sequence;
nd (4) marker was positive in both subpopulation and
onsensus sequence. Although we focused on identifying
ubpopulations that altered the phenotype represented in
he consensus sequence, we examined the entire data set
or the presence of SNPs (=subpopulations) at any site in
he genome.
. Results and discussion
Surveillance of avian inﬂuenza virus (AIV) in wild
irds is crucial to track the emergence, evolution and
pread of viruses, and recent efforts have yielded a ﬂood
f prevalence and sequence data [23]. However, a key
hallenge remains: can we use genotype data to identify
nd predict viruses that pose the greatest threat to human
nd animal health? The advent of NGS and online phe-
otyping tools allow researchers to begin addressing this
hallenge by mining the vast array of sequence data that
s accumulating through ongoing surveillance. This study
emonstrates that approach, using the IRD amino acid
henotyping tool to identify and characterize phenotypic
arkers for increased pathogenicity and host tropism in
ammals to identify AIV of public health signiﬁcance.
Our ﬁrst question was  which molecular markers are
seful for detecting increased pathogenicity and transmis-
ibility in mammals, and are these markers present in the
onsensus sequence of isolates in California (2005–2010)?
ositive marker phenotypes were present within one or
ore of the 206 consensus sequences for 63 (42.3%) of the
49 markers examined (Table 1). Between 19 and 29 posi-
ive markers were detected in each of the 206 isolates undergy and Infectious Diseases 36 (2013) 521– 536 529
investigation. Occurrence data for each of these 63 markers
for all 206 isolates is shown in Supplementary Table 2.
Supplementary material related to this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.cimid.2013.06.003.
The phenotypic markers identiﬁed in our isolates were
not evenly distributed across inﬂuenza segments. The
number of positive markers per segment were: PB2 (17/34,
50%), PB1 (7/16, 43.75%), PB1-F2 (1/1, 100%), HA (20/40,
50%), M1  (3/6, 50%) and M2 (1/2, 50%), PA (6/18, 33.3%),
NP (3/10, 30%) and NS1 (5/16, 31.3%). No positive markers
were detected on the segments encoding the NA (0/2) and
NEP/NS2 (0/4).
We  rejected the null hypothesis that positive mark-
ers were equally distributed across HA subtypes (Table 2).
Thirty-three (33) of the 63 positive markers were signiﬁ-
cantly (P ≤ 0.05) over- or under-represented in particular
subtypes, and these differences were highly signiﬁcant
(P ≤ 0.001) for 21 of the markers. The 33 markers that var-
ied signiﬁcantly among HA subtypes were found primarily
in the HA (n = 18) and PB2 (n = 7) segments, and to a much
lesser extent in PB1 (n = 2), PB1-F2 (n = 1), NS1 (n = 2), PA
(n = 2), and NP (n = 1). None of the phenotypic markers iden-
tiﬁed in the NA, M1  and M2  proteins showed any signiﬁcant
association with HA subtype.
We were interested to see whether HA subtypes that
were found in previous pandemic human inﬂuenza strains
(H1, H2 and H3) [24,25], or that have been reported to cause
zoonotic infections (H5, H7 and H9) [26], had more positive
markers than other HA subtypes. Positive markers occurred
signiﬁcantly less often in subtypes H6, H7, H10 and H11
compared to subtypes H1, H2, H3 and H5. We were some-
what surprised by the paucity of markers in H7 sequences.
The recent emergence of H7N9 in humans in China (Gao
et al., 2013) provided an opportunity to compare mark-
ers with our California H7 sequences. Phenotypic marker
analysis revealed 6 positive markers (PB2 E/D627K/N, PB1
R207K, PB1 I368V, PB1 H436Y, PA V100A, HA Q222L) that
were negative in all Californian isolates analyzed in this
study. Thus, the reduced number of markers in our H7
sequences appears to reﬂect their reduced risk relative to
emerging H7N9 variants in China. Surprisingly, positive
markers occurred signiﬁcantly more frequently in subtype
H4 than any other subtypes except for H1 and H2. This sub-
type has not been associated with seasonal or pandemic
infections in humans, but it has been occasionally isolated
from mammals including pigs, horses, rodents and marine
mammals [27]. These results, coupled with the fact the
H4 subtype can support a highly pathogenic phenotype
[28] suggest that H4 viruses deserve increased attention
as potential threats.
We found the mean number of positive markers per
isolate to vary signiﬁcantly among HA subtypes. Across
all positive markers observed in our study (n = 63), the
highest mean number of positive markers for each iso-
late in a subtype was found in H4, followed by H1 and
H2 (Table 3A). When considering only those markers that
increase virus binding to ˛2,6 linked sialic acid receptors
(n = 14), H1 showed the highest mean number, followed by
H5 and H3 (Table 3B). This result suggests that HA sub-
types most commonly associated with inﬂuenza infections
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Table 2
Distribution of phenotypic markers that varied signiﬁcantly between HA subtypes. Upward and downward arrows indicate that a marker was signiﬁcantly
more or less common, respectively, in that HA subtype when compared against all other subtypes combined. Numbers of virus isolates for each subtype
are  indicated in brackets. Frequencies of phenotypic markers for each subtype were compared according to Fisher’s exact test (↑↑↑, ↓↓↓ p ≤ 0.001, ↑↑,  ↓↓
p  ≤ 0.01, ↑, ↓ p ≤ 0.05, –, not signiﬁcant) (aa, amino acid. For aa: A, Alanine; D, Aspartic Acid; E, Glutamic Acid; F, Phenylalanine; G, Glycine; H, Histidine; I,
Isoleucine; K, Lysine; L, Leucine; M,  Methionine; N, Asparagine; P, Proline; Q, Glutamine; R, Arginine; S, Serine; T, Threonine; V, Valine; Y, Tyrosine).
Gene aa mutation H1 (12) H2 (6) H3 (13) H4 (29) H5 (22) H6 (71) H7 (8) H8 (4) H10 (22) H11 (14) H12 (5)
PB2 T63I – – – – – – – – – ↓↓ –
PB2  I553V – – – – ↑↑ – – – – – –
PB2  D567N – – – – – – ↑ – – – –
PB2  G590S – – ↑↑ – – ↓↓ – – – – –
PB2  A661T – ↑↑↑ – – – – – – – – –
PB2  V667I – – – ↑ – – – – – – –
PB2  A676T – – – – – – – – ↓↓ – –
PB1-F2  N66S – – – – – – – – ↓ – –
PB1  M/V317I – – – ↓ ↓ ↑↑↑ – – ↓ – –
PB1  S375N/T – – – ↑↑↑ – ↓↓ – – – – ↑
PA  E382D – – – – – – ↑↑ – – – –
PA  S409N – – – – – – – ↑ – – –
HA  A/I/P/S/T86V ↓ ↑↑↑ ↓ ↑↑↑ ↑↑↑ ↓↓↓ – – ↓↓ ↓ –
HA  D94N – – – – ↑↑↑ ↓↓↓ – – – – –
HA  S123P ↑↑↑ – – – – ↓↓ – – – – –
HA  N/D124S – – – ↓ – ↓↓↓ – – ↑↑↑ – –
HA  S133A ↑↑↑ – – ↓ – ↓↓↓ – – – ↑↑↑ –
HA  Q/H/I138L/N ↓ – ↓ ↓↓↓ ↑↑↑ – – – ↑↑↑ ↓↓ –
HA  I151T ↑↑↑ ↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↓↓↓ – ↑ ↓↓↓ ↓↓ ↑↑
HA  N154D – – – ↑↑↑ ↓ ↓↓↓ – – – – –
HA  S155N – – – ↑↑↑ ↑↑↑ ↓↓↓ – – ↓↓ ↓ –
HA  T156A ↓↓↓ ↓↓↓ ↑ ↑↑↑ ↑↑ ↑↑↑ – ↓↓ ↓↓↓ ↓↓↓ ↓↓
HA  T188I – – – – – – – – – – ↑
HA  K189R – – ↑↑ – – – – – – – –
HA  N193K – – – – – ↓↓ – – – ↑↑↑ –
HA  S205Y ↑↑↑ – – – – ↓↓ – – – – –
HA  V210I – ↑↑↑ ↑↑↑ ↓↓ ↑↑↑ ↓↓↓ – – ↓↓ ↓ –
HA  A263T – – – ↑↑↑ ↓ ↓↓↓ – – ↓ – –
HA  T315I – – – – – – – – – – ↑↑↑
HA  R497K ↑↑↑ ↑ ↓↓↓ ↓↓↓ ↓↓↓ ↑↑↑ ↓↓ – ↓↓↓ ↑↑↑ –
NP  L136M – ↑ – – – – – – – – –
↓↓↓ 
↓↓↓ NS1  A/P42S – – ↑↑ – 
NS1  T/D/V/R/A127N – – ↑↑ – 
in mammals have an increased number of transmissibility
markers compared to other, predominantly avian HA sub-
types. Alternatively, our selection of markers may  be biased
towards these HA subtypes because these markers were
primarily found in subtypes isolated from mammals. In
some HA subtypes there was a strong contrast between the
total occurrence of a positive marker per subtype and the
mean number of positive markers per isolate. For example,
H4 had 38 positive markers yet the mean per isolate was
only 25.58 ± 1.52. This reﬂects the fact that many positive
markers occurred only in one or a small number of isolates
and were absent in all the other isolates. One intriguing,
but untested, explanation for this pattern is that isolates
with marker-positive phenotypes may  be at a selective dis-
advantage in birds (thus their low frequency), but have a
greater potential for successfully infecting mammals.
The idea that certain strains can more easily infect
mammals was further addressed by answering this
question: were viral subpopulations present at marker
sites in our isolates? Analysis of deep sequencing data
for 24 isolates revealed a total of 11,088 SNPs, of
which 344 occurred at marker positions. Results for
A/mallard/California/6768/2009 (H1N1) are shown in
Table 4, and described below to facilitate interpretation.
Data for all 24 isolates are shown in Supplementary Table↓↓↓ ↑↑ – – – –
↓↓↓ ↑↑ – – – –
3. For the isolate in Table 4, 153 SNPs were present in over
5% of nucleotide reads, and 5 of these SNPs were present
at phenotypic marker positions. One of these 5 SNPs at
marker positions caused a non-synonymous amino acid
substitution at position 271 of the PB2 protein, chang-
ing the threonine (T) found in the consensus amino acid
sequence to an alanine (A) in a viral subpopulation. PB2
T217A is a reported human host marker (Table 1). The
subpopulation presents with a guanine (G) in 6.7% of
nucleotide reads, constituting the viral subpopulation and
causing the observed amino acid substitution, while 93.3%
of nucleotides present with an adenine (A) in the consensus
sequence. At position 127 in the NS1 protein, the posi-
tive marker NS1 127N is found in the consensus sequence
(C in 94.2% nucleotide reads), whereas a viral subpopu-
lation (A in 5.8% nucleotide reads) shows a lysine (K) at
this position, rendering the subpopulation negative for this
marker. A positive marker at this position would have
suggested increased virulence in mammals (Table 1). Two
synonymous changes occurred in subpopulations at PB2
199 and NP 16 (both are reported human host markers
(Table 1)), but both consensus sequence and subpopula-
tion are negative for a phenotypic marker at this position.
One non-synonymous change occurred at position 15 of
the M1  protein (a Y at this aa position is associated with
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Table 3
Occurrence and frequency of all 63 positive phenotypic markers observed in this study (A), and of 14 positive markers for increased virus binding to 2-6 linked sialic acid receptors (B). Numbers of virus isolates
for  each subtype are indicated in brackets.
H1 (12) H2 (6) H3 (13) H4 (29) H5 (22) H6 (71) H7 (8) H8 (4) H10 (22) H11 (14) H12  (5)
A
Total marker occurrence/63 (%) 30/63 (47.6%) 28/63 (44.4%) 30/63 (47.6%) 38/63 (60.3%) 30/63 (47.6%) 34/63 (54%) 26/63 (41.3%) 24/63 (38.1%) 30/63 (47.6%) 26/63 (41.3%) 29/63 (46%)
Mean  # markers per isolate ± s.d. 24.8 ± 1.27 24.8 ± 2.2 23.8 ± 0.8 25.6 ± 1.5 23.6 ± 1.0 21.8 ± 1.2 22.1 ± 1.0 22.8 ± 0.5 21.5 ± 1.5 22.6 ± 1.0 23.6 ± 1.7
B
Total  marker occurrence/14 (%) 6/14 (42.9%) 3/14 (21.4%) 6/14 (42.9%) 3/14 (21.4%) 4/14 (28.6%) 2/14 (14.3%) 1/14 (7.1%) 2/14 (14.3%) 0/14 (0%) 4/14 (28.6%) 3/14 (21.4%)
Mean  # markers per isolate ± s.d. 5.2 ± 0.5 3.00 ± 0.0 3.4 ± 0.7 2.7 ± 0.5 3.7 ± 0.5 2.00 ± 0.0 1.00 ± 0.0 2.00 ± 0.0 0 ± 0 3.1 ± 0.3 2.2 ± 0.5
Table 4
Example of viral subpopulation analysis at phenotypic marker positions as revealed by deep sequencing. The consensus nucleotide is marked in bold. The nucleotide(s) responsible for the positive marker are
highlighted in grey. Columns E–H describe whether phenotypic markers were positive in the subpopulation and negative in the consensus sequence (Consensus neg/Subpop pos), positive in the consensus
sequence and negative in the subpopulation (Consensus pos/Subpop neg) or negative or positive in both (Consensus neg/Subpop neg, Consensus pos, Subpop pos) (aa, amino acid; nt, nucleotide. For aa: A,
Alanine;  D, Aspartic Acid; G, Glycine; I, Isoleucine; K, Lysine; N, Asparagine; R, Arginine; S, Serine; T, Threonine; V, Valine. For nt: A, Adenine; C, Cytosine; G, Guanine; T, Thymine).
Isolate Subtype total # subpop # subpop at
marker pos
Consensus
neg/Subpop pos
Consensus
pos/Subpop neg
Consensus
neg/Subpop neg
Consensus
pos/Subpop pos
Phenotype marker
(aa)
Syn/Non-syn Nucleotide variation
A % C % G % T %
A/mallard/
California/
6768/2009
H1N1 153 5
NS1 N127K
PB2 A199 PB2 A199S Syn 94.2 4.3 1.4 –
PB2  T271A PB2 T271A Non-syn 93.3 – 6.7 –
NP  G16 NP G16D Syn 3.1 1.6 1.6 93.7
M1  V15G, A, D M1 V15I/T Non-syn 0.7 1.9 3.5 93.9
NS1
T/D/V/R/A127N
Non-syn 5.8 94.2 – –
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Table 5
Distribution of viral subpopulations at phenotypic marker positions in a subset of virus isolates (n = 24) as revealed by deep sequencing. Columns E–H
describe whether phenotypic markers were positive in the subpopulation and negative in the consensus sequence (Consensus neg/Subpop pos), positive
in  the consensus sequence and negative in the subpopulation (Consensus pos/Subpop neg) or negative or positive in both (Consensus neg/Subpop neg,
Consensus pos, Subpop pos).
Isolate Subtype Total #
subpop
#  subpops
at marker
pos
Consensus
neg/Subpop
pos
Consensus
pos/Subpop
neg
Consensus
neg/Subpop
neg
Consensus
pos/Subpop
pos
A/mallard/California/6768/2009 H1N1 153 5 1 1 3 0
A/northern pintail/California/3452/2012 H1N1 121 6 2 0 4 0
A/mallard/California/1438/2010 H2N3 56 2 0 0 2 0
A/northern shoveler/California/HKWF1128C/2007 H2N7 887 13 2 6 5 0
A/northern shoveler/California/HKWF1046C/2007 H3N5 653 10 2 3 5 0
A/environment/California/7862/2008 H3N8 1297 44 8 5 30 1
A/mallard/California/5271/2009 H4N6 43 2 0 1 0 1
A/mallard/California/6772/2008 H4N6 2107 98 27 8 62 1
A/mallard/California/8035/2008 H5N2 622 18 5 4 8 1
A/mallard/California/5276/2009 H5N2 20 1 0 1 0 0
A/mallard/California/5359/2009 H5N2 240 9 2 3 4 0
A/mallard/California/8834/2008 H5N9 281 6 2 0 4 0
A/mallard/California/8429/2008 H6N1 873 28 8 1 19 0
A/green-winged teal/California/7972/2008 H6N2 57 0 0 0 0 0
A/environment/California/7451/2010 H7N3 100 6 1 2 3 0
A/northern shoveler/California/HKWF1372C/2007 H7N3 287 6 0 0 6 0
A/green-winged teal/California/1841/2009 H7N3 92 5 1 3 1 0
A/mallard/California/1390/2010 H7N5 203 7 2 2 2 1
A/northern shoveler/California/3628/2011 H10N3 99 2 0 0 2 0
A/mallard/California/9704/2008 H10N7 429 11 1 4 6 0
A/environment/California/7650/2008 H11N8 341 5 0 3 2 0
A/mallard/California/6634/2008 H11N9 2029 58 14 13 28 3
A/northern shoveler/California/3483/2010 H12N5 55 0 0 0 0 0
marker in our isolates signiﬁcantly enhances transmissionA/American wigeon/California/6610/2008 H12N5 43 
increased virulence in mammals (Table 1)), changing the
methionine (M)  in the consensus amino acid sequence to
a glycine (G) (G in 3.5% nucleotide reads), an alanine (A) (C
in 1.9% nucleotide reads) and an aspartic acid (D) (A in 0.7%
nucleotide reads) in viral subpopulations. The phenotypic
marker is negative in both the consensus sequence and the
viral subpopulations.
Supplementary material related to this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.cimid.2013.06.003.
Deep sequencing results for all 24 isolates are summa-
rized in Table 5, and provided in full in Supplementary
Table 3, and Table 1 contains information which positive
markers were positive in subpopulations. Comparison of
subpopulation phenotypes with consensus sequence phe-
notypes yielded these results: (1) 61 markers were positive
in the consensus sequence, but negative in the subpopula-
tion; (2) 78 markers were positive in the subpopulation,
but negative in the consensus sequence; (3) 197 markers
were negative in both the subpopulation and the consensus
sequences, and (4) 8 markers were positive in both subpop-
ulation and consensus sequences. Overall, subpopulations
present at marker positions were signiﬁcantly more likely
to be negative (258/344) than positive (86/344). Nearly all
of the marker-positive subpopulations (78/86) were associ-
ated with consensus sequences that were marker-negative.
Likewise, nearly all of the marker-positive consensus
sequences were associated with negative subpopulations
(61/69). Our analysis revealed signiﬁcant variation in
important phenotypic markers among avian isolates, and
showed that consensus sequences do not fully convey2 0 1 1 0
an isolate’s potential for increased transmissibility and
pathogenicity in mammals.
Although our analysis revealed signiﬁcant variation
in the occurrence and frequency of important markers
among isolates and HA subtypes, functional studies in vitro
and in vivo are needed to conﬁrm the signiﬁcance of
these changes, as conﬂicting results have been obtained
in the past. For example, a great body of evidence sug-
gests PB2-627 as a determinant for increased mammalian
pathogenicity and host tropism (see Table 1), but other
studies fail to report these ﬁndings [29–32].
Viruses analyzed in our current study were obtained
after a single passage in embryonated chicken eggs to min-
imize potential changes caused by adaptation to chicken
eggs [33]. Future experiments will include passage of can-
didate strains in avian and mammalian systems to evaluate
the relative ﬁtness of strains possessing speciﬁc marker
phenotypes that differ between consensus and subpop-
ulation sequences. The occurrence of a given marker is
expected to change under selective pressure, such as that
seen for viruses exposed to the NA inhibitor oseltamivir
[34,35]. Amino acid mutations associated with drug resis-
tance were identiﬁed in subpopulations of inﬂuenza
patients in the absence of drug-associated selection pres-
sure (before oseltamivir treatment) and became more
dominant in the patient after oseltamivir therapy, and in
virus passage in mammalian cells [34]. If a given positivefrom birds to mammals, we  would expect its frequency to
increase after passage in mammalian cells, possibly becom-
ing dominant in the consensus sequence. Furthermore,
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assage of the same isolate in chicken eggs may  be expected
o result in decreased frequency or total loss of the positive
arker.
. Conclusion
Our analysis revealed signiﬁcant variation in impor-
ant phenotypic markers among avian isolates, and showed
hat consensus sequences do not fully convey an isolate’s
otential for increased transmissibility and pathogenicity
n mammals. Analysis of markers in emerging new viruses
uch as H7N9 in humans, coupled with controlled labo-
atory experiments as described above, will help reveal
hich markers are the most relevant for identifying viruses
hat bear a high risk for humans and animals [36]. Since
irus culture inevitably introduces artiﬁcial changes in the
iral genome, it is critical that we develop the ability to
enerate full genome sequences from samples without
ulture in cells. This will ensure that molecular markers
nvestigated in the laboratory accurately reﬂect genotypes
ccurring in nature.
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